Stratifin accelerates progression of lung adenocarcinoma at an early stage

Lung cancer is the most common cause of global cancer-related mortality, and the most common histological type is adenocarcinoma [1]. Noguchi et al. [2] have demonstrated that adenocarcinoma in situ (AIS) has an extremely favorable prognosis, with a 5-year survival rate of 100 %. AIS shows stepwise progression to early but invasive adenocarcinoma (eIA), which has a relatively poorer outcome, the 5-year survival rate being 75 % [2, 3]. We previously compared the gene expression profiles of AIS with those of eIA associated with lymph node metastasis or a fatal outcome, and screened the differentially expressed genes by cDNA microarray. Among genes showing significantly higher expression in eIA than in AIS, we finally focused on stratifin (SFN, 14-3-3 sigma) [4], and subsequently clarified that its overexpression in eIA is associated with demethylation of its promoter region [5].

14-3-3 is a highly conserved, ubiquitously expressed protein family, associated with many different cellular processes. Among the seven human 14-3-3 isoforms (beta, epsilon, eta, gamma, tau, zeta, and sigma), 14-3-3 sigma has been linked to cancer most directly. 14-3-3 sigma (SFN) was originally identified as a p53-inducible gene that is responsive to DNA-damaging agents [6, 7]. These findings define SFN as a negative regulator of cell cycle progression. However, our analysis of SFN expression in lung adenocarcinoma indicated that it is overexpressed in tumor cells to a greater extent than in normal lung epithelium, and that this overexpression stimulates tumor growth [4]. On the basis of these findings, we speculate that SFN in lung adenocarcinoma cells might have tissue-specific functions and regulate cell cycle progression in a positive manner.

Here, we first examined the function of SFN in lung adenocarcinoma cells. All materials and methods are described in Additional file 1. Using the lung adenocarcinoma cell line A549 transfected with siSFN, cell proliferation, invasiveness, apoptosis, and senescence were analyzed respectively. Suppression of SFN led to a significant decrease in the number of cells and the S-phase subpopulation in comparison with controls (Fig. 1a-c, p <0.001, Student’s t test, Additional file 2: Figure S1). However, we were unable to detect any difference in invasiveness, apoptosis, or senescence between cells treated with siSFN and those treated with siCNT (Additional file 3: Figure S2a-d). Although SFN is reportedly related to apoptosis or senescence [8, 9], we were unable to detect any such association in the present study. This is likely because SFN does not bind to proteins such as BAX or BAD, which regulate apoptosis or senescence in lung adenocarcinoma (data not shown, personal communication). We are investigating the functional network of SFN in lung adenocarcinoma, and the results will be published in the near future.

We next induced stable knockdown of SFN using two individual shRNAs (shSFN#1 and shSFN#2). These shRNAs significantly inhibited the expression of SFN in A549 (Fig. 1d) and reduced the degree of cell growth (Fig. 1e). To evaluate the oncogenic activity of SFN, we injected A549-shSFN#1 and -shSFN#2 intrabronchially into SCID mice, and at 4 weeks after injection [10], all the mice were sacrificed and their lungs were collected. It was found that A549-shSFN#1 and A549-shSFN#2 formed significantly fewer tumors than the control cells (Table 1). Whereas the mice injected with A549-shLuc developed tumors up to 4 mm in size and the number of such tumors was high, the mice injected with A549-shSFN#2 developed just one tumor each, and each tumor was less than 1 mm in size (Fig. 1f). SFN expression was suppressed in the tumors that developed in the A549-shSFN#2 group relative to those that developed in the A549-shLuc group (Fig. 1f).

Moreover, in order to examine the effect of SFN on the metastatic potential of lung adenocarcinoma cells, we intravenously injected A549-shSFN#1 and -shSFN#2 into SCID mice, and sacrificed the mice 8 weeks after injection. We found that A549-shSFN#1 and A549-shSFN#2 did not form any tumors, whereas control cells formed numerous poorly differentiated adenocarcinomas in the lungs (Fig. 1g, Table 1). These data indicated that knockdown of SFN suppressed not only lung tumor formation but also the metastatic potential of lung adenocarcinoma.

While down-regulation of SFN in vitro had no effect on cancer cell migration and invasion (Additional file 3: Figure S2), suppression of SFN expression reduced the dissemination/metastasis of xenograft tumors (Table 1). Although the results of the in vitro and in vivo assays appear contradictory, we consider that growth reduction of A549-shSFN reduced the activity of the tumor cells in mice and finally affected their metastatic or invasive capacity.

Next, to generate transgenic mice exhibiting lung-specific expression of human SFN (hSFN), we ligated a fragment of the surfactant protein C (SPC) promoter to a cDNA for hSFN (Fig. 2a), which was attached to a polyadenylation signal. The transgenic DNA was then injected into pronuclear-stage embryos of ICR (Institute of Cancer Research) mice, and the resulting offspring were screened by genotyping PCR for the presence of the transgene. Twelve founder mice positive for transgene integration were obtained. To confirm the lung-specific expression of the transgene, we performed RT-PCR and IHC to detect hSFN mRNA and protein in the F1 mice. The transgene was expressed in lung tissue (type II alveolar epithelial cells and basal cells in bronchial wall) but not in heart, kidney, liver, or spleen (Fig. 2b, c). We selected two lines that showed the highest hSFN expression in lung (lines 109 and 130, Additional file 4: Figure S3).

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific and highly potent pulmonary carcinogen, induces lung adenoma and adenocarcinoma in various species [11]. Our preliminary experiment showed that 18 % of WT ICR mice developed lung tumors 20 weeks after intraperitoneal (i.p.) administration of NNK. In order to observe the tumorigenic activity of SFN, Tg-SPC-SFN^+/− and WT ICR mice were i.p. administered 4 mg NNK, or saline as a control, and tumorigenicity was assessed for 20 weeks. Lungs of representative mice were periodically examined using animal CT. This revealed that some Tg-SPC-SFN^+/− developed pulmonary tumors from 15 weeks after NNK administration (Fig. 2d). At 20 weeks after NNK administration, 47.8 % of Tg-SPC-SFN^+/− (11/23) had developed lung tumors, whereas only 11.1 % of WT ICR (3/27) had done so (Table 2, Fig. 2e). This difference in the incidence of lung tumors was statistically significant (p <0.001, χ ² test). One Tg-SPC-SFN^+/− mouse developed three tumors, and another developed two simultaneously. The others developed one tumor each. Histologically, all of the tumors were poorly differentiated adenocarcinoma, but intrathoracic dissemination or metastasis was not observed until 20 weeks after NNK administration. Independent evaluation of male and female mice revealed no significant gender difference. Although it is possible that the transgene could have disrupted a locus leading to increased susceptibility to tumor formation, we consider that tumor formation in Tg-SPC-SFN^+/− was caused by hSFN overexpression because we also performed the same experiment using two transgenic lines independently, and the results were similar. All of the tumors that developed in Tg-SPC-SFN^+/− lung expressed hSFN abundantly (Fig. 2f). In contrast, tumors in WT ICR lung showed no hSFN expression, but slight mSFN expression (Additional file 5: Figure S4).

Surprisingly, two of seven Tg-SPC-SFN^+/− mice (28.6 %) developed tumors even though they were not administered NNK (Table 2, Fig. 2e). These results indicate that SFN facilitates not only tumor progression but also tumor initiation, and that it works as an oncogene. Soda et al. found that 100 % of Tg-EML4-ALK mice developed hundreds of adenocarcinoma nodules in both lungs within a few weeks after birth [12]. Although the oncogenic activity of SFN is weaker than that of EML4-ALK fusion kinase, SFN also appears to have the potential to initiate lung adenocarcinoma.

A number of driver oncogenes have been reported, and many patients with lung adenocarcinoma are treated using various drugs targeting these oncogenes. Although these targeting drugs are initially effective, most cancers develop tolerance to them [13]. This phenomenon can be explained by complex alterations of oncogenes and anti-oncogenes in lung adenocarcinoma at the advanced stage [14]. However, according to the multistep carcinogenesis of lung adenocarcinoma [15], the number of such driver oncogenes in early-stage lung adenocarcinoma is expected to be limited, and SFN overexpression is one of the candidates suggested playing an important role in forced cell proliferation. During the course of slow but steady cell proliferation, tumor cells acquire several crucial gene alterations such as ALK translocation, p53 mutation and EGFR amplification. In the present study, we demonstrated that SFN is an oncogenic factor playing a role in the initiation and progression of early lung adenocarcinoma. Since alteration of SFN is observed in most lung adenocarcinomas, even AIS and minimally invasive adenocarcinoma, targeted therapy to block SFN might be a new treatment strategy for patients with early-stage lung adenocarcinoma. Although the mechanism underlying the function of SFN in lung adenocarcinoma progression has not been proved, further analysis of the molecular network of SFN in lung tumor cells is required.